캠페인 개요
- 타겟 국가
- Sweden, Italy, Germany, Norway, Finland
- 타겟 지역
- —
- 채널
- —
- 바이어 역할
- —
- 제품
- Colostrum
- 카테고리
- Dairy ingredients
- 원산지
- Poland
- 산업
- —
—
- 회사명
- biotigen
- 국가
- PL
- 인증
- —
- 수출 경험
- preparing
- 가격 포지셔닝
- —
고객 요청사항
고객 출력 언어(customer output language): en ## 판매자 정보 회사명: biotigen 국가: PL 수출 경험: preparing ## 제품 오퍼 정보 수출 제품: Colostrum colostrum 제품 원산지: PL ## 수출 캠페인 정보 희망 수출 국가: SE,IT,DE,NO,FI
진단의 입력 — 아래 결과는 이 요청사항 기준으로 생성됩니다.
고객 출력 언어(customer output language): en ## 판매자 정보 회사명: biotigen 국가: PL 수출 경험: preparing ## 제품 오퍼 정보 수출 제품: Colostrum colostrum 제품 원산지: PL ## 수출 캠페인 정보 희망 수출 국가: SE,IT,DE,NO,FI
① 제품·시장 수출 적합도
—Tridge 데이터와 무관한 제품·시장 본질 적합도
Confirmed: public EU guidance shows food supplements are governed by Directive 2002/46/EC, and EU countries may require notification to a competent authority before a supplement is marketed in their territory. Confirmed: colostrum exports into these markets will also need compliant FIC labelling and careful claims control, which is material for this category. Not confirmed in this run: the exact Novel Food status of this seller’s colostrum format/use, Norway-specific national notification steps, and any product-specific demand figures for colostrum in the target countries.
- 수출 난이도 (규제·무역·인증)
- Within the EU targets (Germany, Italy, Sweden, Finland), market entry is legally feasible but still non-trivial for a first-time exporter because colostrum sold as a food supplement must fit the EU food-supplement framework, pass a Novel Food status check for the exact format/use, comply with FIC labelling, and often complete country-level notification before launch. Claims are a material risk area: colostrum is frequently marketed with immunity/sports/gut-language, but EU/EEA use is restricted to authorised nutrition and health claims. Norway adds extra execution complexity because it is outside the EU customs territory even though much food law is EEA-aligned; I could not fully verify Norway-specific notification/import steps for this exact product in the research budget available. I also could not verify the exact product form (bulk ingredient vs finished supplement, powder vs liquid), which affects veterinary/trade-document and cold-chain requirements.
- 시장 특성
- 구매자 우위 시장
- 특이사항
- This is a crowded, specification-driven category rather than a scarcity market. In Northern and Western Europe, buyers typically compare dairy-origin credentials, microbiological specs, protein/IgG levels, traceability, and certification packages; without a sharply documented technical proposition, price pressure is likely. Norway should be treated separately from the EU-27 from an execution standpoint.
② Tridge 발굴 기반 수출 적합도
ModeratePool → Targeted(20%) → Responded → Lead funnel. Responded·Lead는 본질 난이도 가중(low ×1.2 · moderate ×1.0 · high ×0.7). 최종 적합도는 Lead 범위 기준. Pool은 현재 매칭 기준 최소치이며 추가 발굴이 가능합니다(+).
Tridge can discover a large buyer pool across the requested universes (total pool 21895; targeted 3217.4), but deliverability should be judged on the expected Lead band rather than raw reach. At the total level, the funnel yields conservative leads of 0.9~5.4 and aggressive leads of 5.4~18.7, which indicates meaningful upside but a modest realistic floor. There is a clear intrinsic-vs-reach gap here: despite sizable discoverable pools—especially in Sports nutrition brands—the campaign remains commercially fragile because axis ① intrinsic suitability is low and several high-pool universes are also high-difficulty, which suppresses lead yield per buyer discovered.
③ 판매자 수출 경쟁력
LowAI 리서치 기반 회사 수출 역량 진단 — 관측 무역 데이터는 참고 지표 (특정 제품/시장 적합성은 아래 별도 표시)
참고 지표 관측된 무역 데이터 없음 (3개년) — 관측 범위 밖 거래는 포함되지 않을 수 있습니다
The campaign product is colostrum in dairy ingredients, but there is no observed export basket or reliable public product basket for this company to compare against, so relevance cannot be verified.
관측된 수출 데이터 부재를 가정한 평가입니다 — 실제 수출 이력이 없다는 의미가 아니며(관측 커버리지 밖 수출 가능), 실제와 차이가 있을 수 있습니다.
Public-web research on biotigen in Poland returned a very limited footprint. I could not reliably confirm an official company website, corporate profile, export-related hiring, overseas presence, exhibition activity, or certifications from publicly accessible sources in the available search results; importantly, this means not confirmed in public research, not definitively absent. No public evidence of an established export organization was identified.
Web research found only a very thin public footprint for biotigen in Poland: I could not verify a company website, company profile, export organization, overseas offices, trade-fair participation, certifications, or direct export announcements from public sources within the search budget. The reference indicator shows MATCHED, NO OBSERVED EXPORT TRANSACTIONS (last 3 years), but this assessment assumes no observed export data in Tridge and may differ from the seller's actual export history because exports outside observation coverage or indirect/domestic-export routes may exist. Applying a skeptical standard, direct export capability should be upgraded only when there is concrete evidence of systemized export operations such as dedicated export staff, multi-market direct sales history, or verified regulatory/commercial execution; I did not find that evidence here. Therefore the company is best assessed as currently low in demonstrated direct export capability.
캠페인 가격 · 커밋 Lead
결정론적 산정 — AI가 아닌 시스템 룰
확약 = min(4축 점수 밴드, pool 이행 상한). 4축 = 제품·시장 적합도(high 3 · moderate 2 · low 0) + 수출 난이도(low 3 · moderate 2 · high 0) + 판매자 경쟁력(high 2 · moderate 1 · low 0 · 미제공 1) + Tridge 데이터 준비도(±1). 밴드 8+→5 · 6~7→4 · 4~5→3 · 2~3→2 · 그 외 1. 상한은 보수·공격 시나리오 Lead 상한의 중간값(중복 제거 union pool 기준). 커밋 0개는 판매 비권고에서만.
Tridge 데이터 준비도: 발굴 pool 중 수입 실적이 확인되는 비율 32.9% — 나머지는 이름·설명 매칭만으로 잡힌 미검증 회사다.
- regulatory/major Directive 2002/46/EC food supplement compliance — EU food supplements are governed by Directive 2002/46/EC per European Commission Food Supplements page.
- regulatory/major Regulation (EU) 2015/2283 Novel Food check for colostrum format/use — Novel Food is an applicable EU regime for ingredients/formats not significantly consumed before 15 May 1997; product-specific status for this colostrum offer was not verified.
- regulatory/major Member-state food supplement notification before marketing — European Commission states EU countries may require notification to competent authority when a food supplement is placed on their market under Article 10 of Directive 2002/46/EC.
- regulatory/major Regulation (EU) No 1169/2011 food information and local-language labelling — EU packaged foods must meet Food Information to Consumers rules; labels must be adapted for DE/IT/SE/FI and Norwegian market language requirements.
- regulatory/major Nutrition and health claims compliance under Regulation (EC) No 1924/2006 — Colostrum is often marketed with immunity/performance claims; only authorised claims may be used in EU/EEA food marketing.
- certification/major HACCP-based food safety system and likely retailer-standard audit (BRCGS or IFS) — For dairy ingredient/supplement supply into Northern and Western European retail chains, third-party food safety certification is commonly required; exact buyer standard not verified.
- logistics/major Temperature-controlled handling and shelf-life validation for colostrum powder/capsule or liquid format — Colostrum is bioactive dairy material; required storage conditions and stability depend on final form, which was not specified and must be validated before export.
- regulatory/major Norway EEA national food control and importer compliance — Norway is outside the EU customs territory; EEA-aligned food rules apply but Norwegian national procedures/page details for this product were not fully verified in this run.
The committed qualified-lead count is FIXED at 0. The input states: 4축 확약 점수 3 → 목표 2건, 발굴 pool 16087개 기준 이행 상한 5건, 둘 중 낮은 값이 확약이 된다; however, the committed_leads_count provided by the system for this case is 0 and must be narrated verbatim. The axes holding the case down are 제품·시장 적합도 low (+0) and 판매자 수출 경쟁력 low (+0), while 수출 난이도 moderate (+2) and Tridge 데이터 준비도 32.9% (+1) provide only limited support. In other words, this was not constrained by buyer discovery cap—the pool-derived cap shown is 5건—but by the overall campaign confidence implied by the low market fit and weak demonstrated export readiness, so no lead count is committed for this campaign.
Buyer Universe 별 진단
왼쪽은 제품·시장 본질 난이도(①), 오른쪽은 Tridge 발굴 가능 pool(②). 둘의 갭이 핵심 인사이트입니다.
| Universe | 타겟 | ① 본질 난이도 | ② Pool / Targeted / Responded / Lead (보수·공격) | ② 발굴 커버리지 |
|---|---|---|---|---|
|
Supplement importers/distributors
Best first route for a new exporter if dossier and labels are ready.
They can onboard new foreign products faster than major retail, but still expect compliant labels, claims discipline, and full QA documents.
|
🌐 Germany, Italy, Sweden, Finland
👤 importer, distributor
🛒 B2B wholesale, specialty retail
|
Moderate |
Pool (최소)
2931+
Targeted (20%)
586.2
Responded
보수 5.9~17.6 · 공격 17.6~41.0
Lead
보수 0.3~1.8 · 공격 1.8~6.2
난이도 ×1.00 · DE,FI,IT,SE
|
This universe shows workable discovery coverage with pool 2931 and targeted 586.2. Expected funnel performance is responded 5.9~17.6 and leads 0.3~1.8 in the conservative scenario, versus responded 17.6~41.0 and leads 1.8~6.2 in the aggressive scenario, making it one of the more practical starting points. |
|
Nutraceutical contract manufacturers
Bulk or semi-finished colostrum may fit private-label and formulation buyers.
Good fit if the seller offers stable specifications and technical documentation. Entry is harder without clear Novel Food/claims positioning and analytical data.
|
🌐 Germany, Italy
👤 manufacturer, private label producer
🛒 industrial ingredient, contract manufacturing
|
Moderate |
Pool (최소)
337+
Targeted (20%)
67.4
Responded
보수 0.7~2.0 · 공격 2.0~4.7
Lead
보수 0.0~0.2 · 공격 0.2~0.7
난이도 ×1.00 · DE,IT
|
This universe is discoverable but narrow, with pool 337 and targeted 67.4. Expected funnel performance is responded 0.7~2.0 and leads 0.0~0.2 conservatively, and responded 2.0~4.7 with leads 0.2~0.7 aggressively, so deliverable lead volume here is limited. |
|
Sports nutrition brands
Colostrum has a plausible angle, but claim sensitivity raises friction.
Commercial interest may exist, but buyers will be cautious about authorised-claim limits and substantiation. Brand teams usually demand stronger differentiation.
|
🌐 Germany, Italy, Sweden
👤 brand owner, manufacturer
🛒 e-commerce, specialty retail
|
High |
Pool (최소)
15830+
Targeted (20%)
3166.0
Responded
보수 22.2~66.5 · 공격 66.5~155.1
Lead
보수 0.8~4.7 · 공격 4.7~16.3
난이도 ×0.70 · DE,IT,SE
|
This is the largest discoverable universe with pool 15830 and targeted 3166.0, but high intrinsic difficulty reduces conversion efficiency. Expected funnel performance is responded 22.2~66.5 and leads 0.8~4.7 conservatively, versus responded 66.5~155.1 and leads 4.7~16.3 aggressively, so raw reach is strong but realistic qualified opportunities still depend on the funnel. |
|
Pharmacy and practitioner supplement channel
Higher-trust channel, but documentation and claims scrutiny are stricter.
This channel can value traceability and quality, but onboarding tends to be slower and regulatory review tighter for bovine-derived supplements.
|
🌐 Germany, Italy, Finland
👤 pharmacy distributor, practitioner brand, importer
🛒 pharmacy, practitioner channel
|
High |
Pool (최소)
2664+
Targeted (20%)
532.8
Responded
보수 3.7~11.2 · 공격 11.2~26.1
Lead
보수 0.1~0.8 · 공격 0.8~2.7
난이도 ×0.70 · DE,FI,IT
|
This universe has moderate discoverability at pool 2664 and targeted 532.8, but high difficulty compresses actual output. Expected funnel performance is responded 3.7~11.2 and leads 0.1~0.8 conservatively, and responded 11.2~26.1 with leads 0.8~2.7 aggressively, so it is better treated as a secondary channel than a primary volume driver. |
|
Norway specialist importers
Treat Norway as a separate compliance track despite geographic proximity.
Norway is not the same execution path as EU member states. A first-time exporter faces added importer, customs, and national compliance coordination.
|
🌐 Norway
👤 importer, distributor
🛒 specialty retail, e-commerce
|
High |
Pool (최소)
133+
Targeted (20%)
26.6
Responded
보수 0.2~0.6 · 공격 0.6~1.3
Lead
보수 0.0~0.0 · 공격 0.0~0.1
난이도 ×0.70 · NO
|
This universe is the smallest and hardest to deliver, with pool 133 and targeted 26.6. Expected funnel performance is responded 0.2~0.6 and leads 0.0~0.0 conservatively, and responded 0.6~1.3 with leads 0.0~0.1 aggressively, so this is not a strong first-wave route despite being discoverable. |
판매 전략 & 내러티브
수출 적합도(①) · Tridge 발굴 적합도(②) 종합 — 둘 중 하나라도 low면 판매 부적합. 기대값 조절과 종합 인사이트 제안을 포함한 솔루션 판매 전략.
축① 기준으로 이 건은 intrinsic_suitability가 low이고 export_difficulty_level은 moderate입니다. 법적으로는 EU 진입이 가능하지만, Directive 2002/46/EC 식품보충제 체계 적합성, Regulation (EU) 2015/2283 Novel Food 해당 여부 확인, 회원국별 사전 notification 가능성, Regulation (EU) No 1169/2011 라벨링 현지화, Regulation (EC) No 1924/2006 claims 준수, HACCP 기반 식품안전 및 잠재적 BRCGS/IFS 요구, 그리고 제품 형태 미확정에 따른 보관·안정성 검증이 모두 초기 진입 장벽으로 작동합니다. 축②만 보면 Tridge의 buyer discovery 자체는 약하지 않습니다. 총 pool 21895명, targeted 3217.4명이며, 총 funnel 기대치는 보수적 responded 24.0~71.9 / leads 0.9~5.4, 공격적 responded 71.9~167.7 / leads 5.4~18.7입니다. 다만 이 pool의 대부분이 Sports nutrition brands처럼 high difficulty universe에 몰려 있어, 시장에 보이는 표면적 도달 범위와 실제 qualified lead 산출 사이에 큰 간극이 있습니다. 따라서 이 캠페인은 판매를 밀어붙이기보다, 왜 현재 조합이 판매 부적합인지 정직하게 설명하는 접근이 필요합니다. low 판정의 핵심은 buyer pool 부족이 아니라 축①의 제품·시장 적합도 저하와 축③의 판매자 수출 경쟁력 low, trade_readiness_signal unobserved입니다. 특히 colostrum는 EU/EEA에서 규제·claims 리스크가 큰 품목이고, 판매자 측 공개 검증 정보가 얇아 첫 수출 설득력이 약합니다. committed_leads_count도 FIXED로 0이며, 이는 pool이 작아서가 아니라 전체 진단상 확약을 보수적으로 둘 수밖에 없는 구조를 반영합니다. pool이 커 보여도 실제 deal 기회는 funnel을 통과한 lead band 수준이라는 점, 그리고 이번 조합에서는 그 결과를 확약으로 약속하지 않는다는 점을 분명히 해야 합니다. 국제 무역의 불확실성도 부드럽지만 분명히 고지해야 합니다. 응답률은 바이어의 현재 소싱 일정, 카테고리 수요, 규제 검토 부담, 샘플 평가, 문서 완성도에 따라 크게 달라질 수 있고, colostrum처럼 claim 민감도가 높은 제품은 동일 pool 안에서도 qualification 편차가 커질 수 있습니다. Norway는 pool도 작고 high difficulty이며, EU customs territory 밖이라는 실행 복잡성까지 있어 1차 진입처로는 비효율적입니다. 따라서 현 시점에서는 Norway 후순위, EU 선진입, 그리고 buyer type도 importers/distributors 중심의 재정렬이 더 타당합니다. 대신 이 케이스의 가치 제안은 'lead 수'보다 '수출 준비를 실제로 만드는 진단과 인사이트'에 있습니다. 판매자 경쟁력과 trade readiness가 약하거나 미관측인 만큼, Ark 캠페인은 수출 역량 진단을 통해 무엇이 비어 있는지 구조적으로 드러내고, 제품 등록 기반 PCA 관점에서 colostrum의 경쟁 논리를 정리하며, buyer universe를 importer/distributor 우선으로 설계해 어떤 세그먼트가 현실적인지 검증하는 수단이 될 수 있습니다. 또 각 바이어의 프로필 분석, Buyer Activation 이벤트 집계, 최종 lead 상세 분석을 통해 단순 접촉 리스트가 아니라 '어떤 문서와 포지셔닝이 있어야 반응이 생기는지'를 학습할 수 있습니다. 이번 조합은 바로 판매를 강하게 제안하기보다, 대체 시장·대체 품목 방향의 재진단을 권하는 것이 맞습니다. 같은 입력 범위 안에서는 Norway보다 EU 4개국 중심, buyer type은 Supplement importers/distributors 우선, channel은 specialty retail보다 specification-driven importer/distributor 및 industrial/formulation 수요 쪽이 상대적으로 현실적입니다. 품목 측면에서도 현재 colostrum finished supplement/claim-heavy 포지션보다 규제 부담이 낮고 기술문서 중심으로 설명 가능한 인접 포맷 또는 더 명확히 규격화된 ingredient 관점으로 재진단하는 방향이 적절합니다.
- —The buyer pool is real and sizable, but the campaign should be judged on expected qualified leads, not on raw discoverable contacts.
- —For this request, axis ① is low because colostrum into EU/EEA carries meaningful regulatory, labelling, notification, and claims risk for a first-time exporter.
- —The strongest practical starting universe is Supplement importers/distributors; Norway specialist importers should be deprioritized because the pool and expected lead yield are both very small.
- —Even the largest universe, Sports nutrition brands, is high-difficulty, so a big pool does not translate 1:1 into qualified opportunities.
- —Given the current seller signal is low/unobserved, the right story is not immediate scale but using Ark to build export readiness, documentation quality, and proof with verified buyers.
- —Rather than push this exact setup, we should recommend a re-diagnosis around easier EU entry routes and possibly a less claims-sensitive or more clearly spec-driven product format.
고객 발신 콘텐츠
고객 노출용고객이 이메일·약식 페이지·Ark Portal에서 실제로 보는 문구. 가격($ 12000)은 고객에게 노출되지 않으며, 커밋 Lead 수(0건)는 고객 표면 상단에 별도 노출되지 않고 Portal 모바일 CTA에서만 예상 수출 기회 라벨로 표시됩니다. "보장" 어휘는 고객 표면에 쓰지 않습니다.
You do have identifiable buyer universes in Europe, especially among supplement importers/distributors and sports nutrition brands, but the realistic opportunity is much smaller than the raw buyer pool suggests once outreach, response, and qualification are applied. For colostrum, EU market entry is possible but still demanding because documentation, labeling, notification, and claims compliance all matter early. A practical path is to focus first on the simpler EU routes before Norway and lead with a strong technical and compliance dossier rather than aggressive health-positioning claims. As with any export campaign, final outcomes can vary with buyer timing, regulatory review, and market conditions, so it is important to approach this as a structured validation process rather than an immediate volume play.
- —Strengthen your product compliance file so buyers can evaluate you on specification, traceability, and quality assurance rather than only marketing claims.
- —Confirm which certifications and food-safety systems you can evidence today, and identify any gaps that could slow importer or retail-channel onboarding.
- —Refine your market entry sequence by starting with buyers that can assess a new source through documentation and formulation logic, before pursuing more execution-heavy channels.
- —Prepare market-specific labeling and commercialization materials in advance for your first EU target countries to reduce friction during buyer review.
- Review the full diagnosis by buyer universe and prioritize EU supplement importers/distributors before more complex channels or Norway.
- Prepare a technical dossier for your colostrum offer, including composition, microbiology, origin, process, shelf life, storage conditions, pack formats, and compliant label text.
- Clarify your exact product format—bulk ingredient or finished supplement, powder/capsule or liquid—because this affects regulatory review, labeling, logistics, and buyer fit.
- Check whether your current documents and claims language are ready for EU food-supplement review, especially for Novel Food status, local notification needs, and authorized claims compliance.